Insider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sells 37,656 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 37,656 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the transaction, the chief executive officer now directly owns 995,195 shares of the company’s stock, valued at approximately $597,117. This trade represents a 3.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CytomX Therapeutics Trading Up 0.1 %

CTMX opened at $0.67 on Friday. CytomX Therapeutics, Inc. has a 1-year low of $0.56 and a 1-year high of $5.85. The stock’s fifty day simple moving average is $0.76 and its 200 day simple moving average is $0.98. The stock has a market cap of $53.41 million, a PE ratio of 3.92 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $38.09 million for the quarter, compared to analysts’ expectations of $13.53 million. Equities analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

A number of large investors have recently added to or reduced their stakes in CTMX. Miller Financial Services LLC bought a new stake in CytomX Therapeutics in the 4th quarter valued at $26,000. Traphagen Investment Advisors LLC bought a new position in CytomX Therapeutics during the 4th quarter worth $31,000. Algert Global LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter worth $35,000. Velan Capital Investment Management LP bought a new position in shares of CytomX Therapeutics in the fourth quarter worth $36,000. Finally, Aspire Growth Partners LLC bought a new position in shares of CytomX Therapeutics in the fourth quarter worth $42,000. Institutional investors own 67.77% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on CTMX shares. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of CytomX Therapeutics in a report on Friday, March 7th. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.02.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.